Clarity Pharmaceuticals Ltd (CLRPF)

$3.35 +0.23 (7.37%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 22,000
Avg Vol 6,458
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 60%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as gli...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 2 9209 4037
Fax: 61 2 9209 4037
Address:
National Innovation Centre, 4 Cornwallis Street Eveleigh, Sydney, Australia
Mangiathis
Mangiathis Apr. 11 at 6:04 PM
$CLRPF
0 · Reply
fda_tracker
fda_tracker May. 8 at 1:05 PM
$CLRPF Phase 2 trial w/est May completion date NCT05407311: https://www.clinicaltrials.gov/study/NCT05407311 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
fda_tracker
fda_tracker Oct. 17 at 1:05 PM
$CLRPF Phase 2 trial w/est Oct completion date NCT05407311: https://www.clinicaltrials.gov/study/NCT05407311 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
fda_tracker
fda_tracker Oct. 16 at 1:05 PM
$CLRPF Phase 2 trial w/est Oct completion date NCT04438304: https://www.clinicaltrials.gov/study/NCT04438304 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
fda_tracker
fda_tracker Sep. 11 at 1:05 PM
$CLRPF Phase 2 trial w/est Sep completion date NCT05613842: https://www.clinicaltrials.gov/study/NCT05613842 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
fda_tracker
fda_tracker Aug. 11 at 1:05 PM
$CLRPF Phase 2 trial w/est Aug completion date NCT04438304: https://www.clinicaltrials.gov/study/NCT04438304 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
Latest News on CLRPF
No data available.
Mangiathis
Mangiathis Apr. 11 at 6:04 PM
$CLRPF
0 · Reply
fda_tracker
fda_tracker May. 8 at 1:05 PM
$CLRPF Phase 2 trial w/est May completion date NCT05407311: https://www.clinicaltrials.gov/study/NCT05407311 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
fda_tracker
fda_tracker Oct. 17 at 1:05 PM
$CLRPF Phase 2 trial w/est Oct completion date NCT05407311: https://www.clinicaltrials.gov/study/NCT05407311 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
fda_tracker
fda_tracker Oct. 16 at 1:05 PM
$CLRPF Phase 2 trial w/est Oct completion date NCT04438304: https://www.clinicaltrials.gov/study/NCT04438304 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
fda_tracker
fda_tracker Sep. 11 at 1:05 PM
$CLRPF Phase 2 trial w/est Sep completion date NCT05613842: https://www.clinicaltrials.gov/study/NCT05613842 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
fda_tracker
fda_tracker Aug. 11 at 1:05 PM
$CLRPF Phase 2 trial w/est Aug completion date NCT04438304: https://www.clinicaltrials.gov/study/NCT04438304 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply